No one disputes that Zetia can lower levels of LDL "bad" cholesterol by 15 percent to 20 percent -- that had been shown in previous trials. However, whether that reduction led to any greater lowering of heart attack or stroke risk had remained unclear.
"These results are very important considerations on how we treat patients with elevated cholesterol and will very likely impact the way we choose drugs to lower cholesterol and eliminate plaque," Dr. Howard Weintraub, clinical director of the Center for the Prevention of Cardio-Vascular Disease at New York University Medical Center, said at the time.
After the Enhance results were released in January, officials at the U.S. Food and Drug Administration said they would review the medication's effectiveness, but only after they get a final report, which was not due for several months.
And since January, according to news reports, sales of the once-blockbuster drug have slumped.
More information
There's more on lowering cholesterol at the American Heart Association.
-- HealthDay Staff
SOURCES: Steven Nissen, M.D., chairman, department of cardiology, Cleveland Clinic; Howard Weintraub, M.D., clinical director, Center for the Prevention of Cardio-Vascular Disease, New York University Medical Center, and clinical associate professor, NYU School of Medicine, New York City; Associated Press
| Copyright©2008 ScoutNews,LLC. All rights reserved |